Akero Therapeutics posted a net loss of $81.6 million for Q3 2025 as it ramped up clinical trial activity for its lead candidate EFX. Increased spending on CROs and CMO services pushed R&D expenses higher, while cash reserves remained strong.

Akero Therapeutics posted a Q2 2025 net loss of $70.5 million, or -$0.86 per share, driven by increased R&D spending for Phase 3 trials. The company ended the quarter with $1.086 billion in cash, cash equivalents, and marketable securities, sufficient to fund operations into 2028.

Akero Therapeutics reported a net loss of $70.7 million in the first quarter of 2025, primarily driven by increased R&D expenses for its Phase 3 SYNCHRONY program. The company highlighted positive Phase 2b SYMMETRY study results showing statistically significant reversal of compensated cirrhosis due to MASH with efruxifermin (EFX), and a strong cash position of over $1.1 billion following a public offering in January 2025.

Akero Therapeutics reported a net loss of $70.024 million for Q4 2024, compared to a net loss of $55.186 million in Q4 2023. The company's total assets increased to $825.886 million, up from $580.271 million in the previous year. Research and development expenses saw a notable increase, reflecting advancements in their clinical programs.

Akero Therapeutics reported cash, cash equivalents and short and long-term marketable securities of $787.1 million as of September 30, 2024. The first patient was dosed in the Phase 3 SYNCHRONY Outcomes study.

Akero Therapeutics reported second quarter financial results, including cash, cash equivalents and marketable securities of $848.3 million as of June 30, 2024. The company believes its current resources will fund Phase 3 SYNCHRONY studies through primary endpoint readouts and its operating plan into the second half of 2027.

Akero Therapeutics reported first quarter financial results, highlighting significant advancements in the clinical development of EFX and a strong cash position of over $900 million, expected to fund operations into the second half of 2027.

Akero Therapeutics reported increased research and development expenses due to ongoing clinical trials and manufacturing for potential marketing applications. The company's cash, cash equivalents, and marketable securities were $569.3 million as of December 31, 2023, expected to fund operations into 2026.

Akero Therapeutics reported its third quarter financial results, highlighting the ongoing Phase 3 SYNCHRONY studies and the progress of its lead product candidate, EFX, in treating NASH. The company's cash position is strong, expected to fund operations into 2026.

Akero Therapeutics reported progress in the clinical development of EFX, highlighted by positive results from the Phase 2b SYMMETRY Cohort D study. The company raised $334.8 million in net proceeds, strengthening its cash position as it prepares to initiate Phase 3 SYNCHRONY studies.

Akero Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2023.

Akero Therapeutics reported fourth quarter and full year financial results for the period ending December 31, 2022. The company's cash, cash equivalents and short-term marketable securities were $351.4 million. Research and development expenses for the quarter were $18.3 million, while general and administrative expenses were $7.1 million. Total operating expenses for the quarter were $25.4 million.

Akero Therapeutics reported third quarter financial results, highlighting positive Week 24 results from the Phase 2b HARMONY study evaluating EFX in the treatment of adult patients with pre-cirrhotic NASH (F2-F3) and the closing of an upsized underwritten public offering of common stock for gross proceeds of approximately $230.0 million.

Akero Therapeutics reported second quarter financial results, highlighting a $25 million equity investment from Pfizer and a $100 million term loan facility from Hercules Capital to support the development of efruxifermin (EFX). The company is progressing with its Phase 2b HARMONY and SYMMETRY studies and expects to report HARMONY results in September.

Akero Therapeutics reported first quarter financial results with cash, cash equivalents, and short-term marketable securities totaling $165.4 million. The company's operating expenses were $26.1 million, resulting in a net loss of $26.0 million, or $0.74 per share.

Akero Therapeutics reported its fourth quarter and full year financial results for 2021, highlighting the continued advancement of its clinical trials for efruxifermin (EFX) in NASH patients and anticipation for Phase 2b HARMONY study results in Q3 of the year.

Akero Therapeutics reported third quarter financial results with focus on advancing efruxifermin (EFX) through Phase 2b clinical trials for NASH treatment.

Akero Therapeutics reported its second quarter financial results, highlighting the potential of efruxifermin (EFX) as a treatment for both pre-cirrhotic (F2/F3) and cirrhotic (F4) NASH. The company is set to initiate its second Phase 2b clinical trial in patients with late-stage cirrhotic NASH (F4).

Akero Therapeutics reported its first quarter financial results, highlighting continued progress in developing treatments for non-alcoholic steatohepatitis (NASH).

Akero Therapeutics reported results from its Phase 2a BALANCED study in biopsy-confirmed NASH patients, suggesting that efruxifermin (EFX) has the potential to be a foundational monotherapy for treatment of NASH.

Akero Therapeutics reported strongly positive histological data from their FGF21 analog, efruxifermin (EFX), and raised more than $216 million to enable continued development of EFX.

Akero Therapeutics reported positive histological results for their FGF21 analog, efruxifermin (EFX), observing improvements in NASH histological parameters after 16 weeks of treatment. Clinically meaningful improvements in glycemic control, weight loss, and lipoproteins were also observed in the BALANCED study.

Akero Therapeutics reported its first quarter financial results, emphasizing the progress of AKR-001 as a potential treatment for NASH. The company highlighted the significant reductions in liver fat and ALT observed in the BALANCED study and is on track to initiate a Phase 2b clinical trial in the first half of 2021.

Akero Therapeutics reported on their progress in clinical and manufacturing development, highlighting the advancement of AKR-001 and a strong cash position to support its continued development.